eXoZymes Inc trading resumes

Written by Emily J. Thompson, Senior Investment Analyst

Source: Business Insider

Updated: Mar 17 2025

0mins

EXOZ0%

Should l Buy EXOZ?

Source: Business Insider

Trading Resumption: eXoZymes (EXOZ) Inc has resumed trading after a halt due to volatility concerns and leadership changes within the company.
Leadership Changes: The company's president and chairman, Hayat, is transitioning out of his roles as part of the recent organizational changes.

Trade with 70% Backtested Accuracy

Stop guessing "Should I Buy EXOZ?" and start using high-conviction signals backed by rigorous historical data.

Analyst Views on EXOZ

About EXOZ

eXoZymes Inc, formerly Invizyne Technologies, Inc., is an artificial intelligence (AI) engineered enzyme that can transform sustainable feedstock into essential chemicals, medicines, and biofuels. The Company has developed a platform that offers the tools and insight to control and optimize nature’s own biological processes, enabling their partners to replace traditional chemical production methods with a new sustainable and non-polluting alternative. The Exozymes are advanced enzymes engineered using AI to thrive in a bioreactor outside of living cells.

About the author

Emily J. Thompson

Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.

Monday 7/7 Insider Buying Report: EXOZ, IAF

Jul 07 2025NASDAQ.COM

Insider Purchases: CEO Michael Heltzen of Exozymes purchased 1,040 shares at $10.22 each, while Director Moritz A. Sell bought $9,000 worth of Aberdeen Australia Equity Fund shares at $4.50 each, marking their first purchases in the past year.
Stock Performance: Exozymes stock is currently trading lower than Heltzen's purchase price, while Aberdeen Australia Equity Fund has seen a slight decline of 0.9% on the same day.

Bringing clarity and precision to the cell-free space by introducing exozymes

Apr 21 2025Newsfilter

Introduction of Exozymes: The term 'exozymes' has been introduced in a cover story published in GEN Biotechnology to clarify the concept of cell-free biomanufacturing, which allows for chemical production without living cells. This initiative aims to foster innovation and streamline partnerships in the field.
eXoZymes Inc. Overview: eXoZymes Inc., a pioneer in AI-engineered enzymes, is leading the development of sustainable biomanufacturing methods that replace traditional chemical processes with eco-friendly alternatives, enhancing the scalability and efficiency of producing essential chemicals and medicines.

BioClick – an enzyme engineering game-changer, launched by eXoZymes and supported by a $300K NIH grant

Apr 10 2025Newsfilter

eXoZymes Launches BioClick Initiative: eXoZymes Inc. has introduced BioClick, a project aimed at enhancing enzyme engineering for advanced chemical reactions, supported by a $300K NIH grant. This initiative focuses on group transfer reactions and aims to revolutionize the creation of medicines and nutraceuticals.
Advancements in Enzyme Engineering: The BioClick approach incorporates artificial intelligence and high-throughput screening to accelerate the development of new drugs and improve existing ones, potentially unlocking previously inaccessible small molecules for medical applications.

eXoZymes appoints experienced biomanufacturing executive, Damien Perriman, as CCO

Apr 02 2025Newsfilter

Leadership Appointment: eXoZymes Inc. has appointed Damien Perriman as Chief Commercial Officer to drive commercial growth and partnerships, leveraging his extensive experience in biotechnology commercialization.
Innovative Biomanufacturing: The company focuses on developing AI-engineered enzymes, known as exozymes, which aim to revolutionize sustainable chemical production by overcoming limitations of traditional methods and enhancing scalability.